Canada Fires Back At Trump: Up to 50% Tariffs on $20 Billion of US Goods
Canada hit back at Trump with tariffs of up to 50% on $20B of U.S. goods, escalating the trade war ahead of Sept. 8.
Read original at benzingaStocks · News reference
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd (GIBO), Novocure Ltd (NVCR), Cleveland-Cliffs Inc (CLF), Merlin Inc (MRLN), Medpace Holdings Inc (MEDP), Oatly Group AB (OTLY), Imax Corp (IMAX), United Rentals Inc (URI), Oceaneering International Inc (OII), and Quest Diagnostics Inc (DGX).
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 2:20 PM
- Checked
- Jul 23, 2026, 2:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Schumer, Pritzker and Others Slam Trump’s Canada Tariffs: ‘Economic Warfare’ Could Raise Costs for Americans
Schumer warned Trump’s Canada tariffs could raise costs for American families and manufacturers, urging Republicans to challenge the trade policy.
Read original at benzingaMike Pence Warns Trump 'The Last Thing We Need' Is a Canada Trade War, Says Tariffs Could Hurt American Families and Businesses
Former VP Mike Pence warns escalating US-Canada tariffs could harm Americans, urges Trump to negotiate instead of deepening conflict.
Read original at benzingaTrump’s 50% Canada Auto Tariff Shock: These ETFs Could Be in the Crosshairs
Trump’s proposed 50% tariff on Canadian autos could hit automakers and supply chains. Here are the ETFs most exposed to the trade-war shock.
Read original at benzingaGlobal Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight
The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
Read original at globenewswire-incQuest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation
Read original at benzinga